307 related articles for article (PubMed ID: 19048841)
1. [Bismuth preparations in the treatment of patients with gastric and duodenal ulcer disease].
Maev IV; Samsonov AA; Golubev NN
Klin Med (Mosk); 2008; 86(9):57-63. PubMed ID: 19048841
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of colloid bismuth subcitrate (De-Nol) in gastropathies induced by nonsteroid anti-inflammatory drugs: an open controlled 4-week trial].
Karateev AE; Nasonov EL; Radenska-Lopovok SG
Ter Arkh; 2005; 77(2):46-9. PubMed ID: 15807452
[TBL] [Abstract][Full Text] [Related]
3. [Effect of bismuth salts in elimination of Helicobacter pylori from gastric mucosa in patients with duodenal ulcer].
Romańczyk T; Nowakowska-Duława E; Nowakowska M; Rogala-Zawada D; Kłuciński P
Med Dosw Mikrobiol; 1993; 45(2):209-12. PubMed ID: 8309299
[TBL] [Abstract][Full Text] [Related]
4. Site-and cytoprotective drugs in the short-term treatment of peptic ulcer. What is their current role?
Bianchi Porro G; Parente F
Ital J Gastroenterol; 1990; 22 Suppl 1():5-10. PubMed ID: 1983422
[TBL] [Abstract][Full Text] [Related]
5. [De-nol in NSAID-induced gastroduodenal lesions].
Cataldo MG; D'Aiuto A; Bongiorno A
Minerva Dietol Gastroenterol; 1990; 36(1):27-30. PubMed ID: 2186304
[TBL] [Abstract][Full Text] [Related]
6. Present and future treatment of peptic ulcer and potential role of DE-NOL.
Scand J Gastroenterol Suppl; 1982; 80():49-57. PubMed ID: 6761852
[No Abstract] [Full Text] [Related]
7. [Morphology of the gastric mucosa in patients with duodenal ulcer treated with bismuth-containing drugs].
Mach T
Folia Med Cracov; 1995; 36(1-4):53-75. PubMed ID: 8834668
[TBL] [Abstract][Full Text] [Related]
8. [Therapy of peptic ulcer and chronic gastritis with bismuth salts].
Rösch W
Z Gastroenterol; 1987 Sep; 25 Suppl 4():34-40. PubMed ID: 3687149
[TBL] [Abstract][Full Text] [Related]
9. [The use of bismuth tripotassium dicitrate (De-Nol), a promising line of pathogenetic therapy for irritated bowel syndrome with diarrhea].
Iakovenko EP; Agafonova NA; Pokhal'skaia OIu; Kolganova AV; Nazarbekova RS; Ivanov AN; Davletshina IV; Popova EV; Prianishnikova AS; Ovchinnikova NI; Iakovenko AV; Aldiiarova MA; D'iachkoava AV; Gioeva IZ
Klin Med (Mosk); 2008; 86(10):47-52. PubMed ID: 19069460
[TBL] [Abstract][Full Text] [Related]
10. A comparative dynamic study of the effectiveness of gastric cytoprotection by vitamin A, De-Nol, sucralfate and ulcer healing by pirenzepine in patients with chronic gastric ulcer (a multiclinical and randomized study).
Patty I; Tárnok F; Simon L; Jávor T; Deák G; Benedek S; Kenéz P; Nagy L; Mózsik G
Acta Physiol Hung; 1984; 64(3-4):379-84. PubMed ID: 6397969
[TBL] [Abstract][Full Text] [Related]
11. Mucosal defences and gastroduodenal disease.
Tasman-Jones C; Maher C; Thomsen L; Lee SP; Vanderwee M
Digestion; 1987; 37 Suppl 2():1-7. PubMed ID: 3622945
[TBL] [Abstract][Full Text] [Related]
12. [Comparative study of the efficacy of ranitidine, cimetidine (Asiloc), De-Nol and spirulina in the treatment of gastric and duodenal ulcer].
Fica V; Andronescu D; Olteanu D
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1987; 39(1):21-35. PubMed ID: 2884709
[No Abstract] [Full Text] [Related]
13. Colloidal bismuth subcitrate (DE-NOL) and tinidazole healed duodenal ulceration with a low relapse rate due to elimination of Campylobacter pylori.
Goodwin CS; Marshall BJ; Blackbourn SJ; Warren JR; Phillips M
J Chemother; 1989 Jul; 1(4 Suppl):838-9. PubMed ID: 16312662
[No Abstract] [Full Text] [Related]
14. [Comparative study of the efficacy of De-Nol and ranitidine in treating duodenal ulcer].
Oproiu A; Pospai D; Cociaşu S; Oproiu C
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1988; 40(4):375-84. PubMed ID: 2905519
[No Abstract] [Full Text] [Related]
15. [Current methods of ulcer therapy and their efficacy and cost].
Grigor'ev PIa; Iakovenko EP; Soluianova IP; Abdulzhapparova MA; Talanova EV; Usankova IN; Prianishnikova AS; Agafonova NA; Guliaev PV; Iakovenko AV; Vasil'ev IV; Obukhovskiĭ BI
Eksp Klin Gastroenterol; 2003; (3):21-5, 116. PubMed ID: 14556541
[TBL] [Abstract][Full Text] [Related]
16. A controlled clinical trial with De-Nol (tripotassium dicitrato bismuthate) in patients with gastric ulcer.
Patty I; Deák G; Jávor T; Mózsik G; Nagy L; Tárnok F
Int J Tissue React; 1983; 5(4):397-401. PubMed ID: 6368445
[TBL] [Abstract][Full Text] [Related]
17. [The role of the polyclinic in raising the efficacy of rehabilitation with peptic ulcer patients].
Grigor'ev PIa; Iakovenko EP; Prianishnikova AS; Kurdanova VF
Ter Arkh; 1992; 64(1):71-5. PubMed ID: 1523569
[TBL] [Abstract][Full Text] [Related]
18. Mucosa protectives: sucralfate and colloidal bismuth subcitrate in peptic ulcer disease.
Tytgat GN; Nio CY
Z Gastroenterol; 1987 Aug; 25 Suppl 3():152-61. PubMed ID: 3660894
[TBL] [Abstract][Full Text] [Related]
19. The effect of tri-potassium di-citrato bismuthate on the duodenal mucosa during ulceration. An ultrastructural study.
Gregory MA; Moshal MG; Spitaels JM
S Afr Med J; 1982 Jul; 62(2):52-5. PubMed ID: 7089785
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacotherapy of non-associated with Helicobacter pylori ulcer].
Grinevich VB; Uspenskiĭ IuP; Shabanova GZh; Sablin OA; Shcherbina NN
Klin Med (Mosk); 2002; 80(10):44-6. PubMed ID: 12471838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
